Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Crosses Below 200 Day Moving Average – Time to Sell?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI)’s stock price passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $10.65 and traded as low as $6.42. Karyopharm Therapeutics shares last traded at $6.51, with a volume of 45,358 shares changing hands.

Analyst Upgrades and Downgrades

A number of brokerages have commented on KPTI. Robert W. Baird cut their price objective on shares of Karyopharm Therapeutics from $75.00 to $54.00 and set an “outperform” rating for the company in a research report on Monday, March 3rd. Royal Bank of Canada reissued an “outperform” rating and set a $45.00 price target on shares of Karyopharm Therapeutics in a report on Thursday, February 20th. Finally, HC Wainwright lifted their price objective on Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a “buy” rating in a report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Karyopharm Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Karyopharm Therapeutics Stock Performance

The company has a market capitalization of $54.79 million, a PE ratio of -6.38 and a beta of 0.11. The firm’s 50-day simple moving average is $8.58 and its 200 day simple moving average is $10.65.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Wednesday, February 19th. The company reported ($3.60) EPS for the quarter, topping analysts’ consensus estimates of ($3.90) by $0.30. The company had revenue of $30.54 million for the quarter, compared to analysts’ expectations of $30.29 million. As a group, equities analysts anticipate that Karyopharm Therapeutics Inc. will post -0.71 earnings per share for the current year.

Institutional Investors Weigh In On Karyopharm Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. FMR LLC boosted its position in Karyopharm Therapeutics by 26.1% during the third quarter. FMR LLC now owns 369,723 shares of the company’s stock worth $307,000 after purchasing an additional 76,510 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Karyopharm Therapeutics by 3.3% in the third quarter. Geode Capital Management LLC now owns 1,355,392 shares of the company’s stock valued at $1,125,000 after buying an additional 43,856 shares in the last quarter. Marshall Wace LLP raised its stake in shares of Karyopharm Therapeutics by 15.3% during the 4th quarter. Marshall Wace LLP now owns 2,401,413 shares of the company’s stock worth $1,633,000 after buying an additional 319,187 shares during the last quarter. TD Waterhouse Canada Inc. purchased a new stake in shares of Karyopharm Therapeutics in the 4th quarter worth about $32,000. Finally, Silverarc Capital Management LLC grew its stake in Karyopharm Therapeutics by 6.7% in the 4th quarter. Silverarc Capital Management LLC now owns 595,990 shares of the company’s stock valued at $403,000 after acquiring an additional 37,524 shares during the last quarter. Institutional investors and hedge funds own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).